Along this line, both EGFR and HER3 have been suggested as prognostic markers in several types of cancer[17, 19–21] as well as drug targets[13, 22, 23], and also to be involved in drug resistance in e.g. breast, lung and ovarian cancers[12, 15, 24, 25]. Here, EGFR is linked to cancer.